questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines ribosomiques
Facteurs initiation chaîne peptidique
Facteurs d'initiation eucaryotes
Facteur-4F d'initiation eucaryote
Facteur-4G d'initiation eucaryote
Facteur-4G d'initiation eucaryote : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Facteur-4G d'initiation eucaryote : Questions médicales les plus fréquentes",
"headline": "Facteur-4G d'initiation eucaryote : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Facteur-4G d'initiation eucaryote : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-07",
"dateModified": "2025-04-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Facteur-4G d'initiation eucaryote"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Facteur-4F d'initiation eucaryote",
"url": "https://questionsmedicales.fr/mesh/D039562",
"about": {
"@type": "MedicalCondition",
"name": "Facteur-4F d'initiation eucaryote",
"code": {
"@type": "MedicalCode",
"code": "D039562",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.835.725.868.500"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Facteur-4G d'initiation eucaryote",
"alternateName": "Eukaryotic Initiation Factor-4G",
"code": {
"@type": "MedicalCode",
"code": "D039603",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Johannes Haybaeck",
"url": "https://questionsmedicales.fr/author/Johannes%20Haybaeck",
"affiliation": {
"@type": "Organization",
"name": "Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria; johannes.haybaeck@i-med.ac.at."
}
},
{
"@type": "Person",
"name": "Jerry Pelletier",
"url": "https://questionsmedicales.fr/author/Jerry%20Pelletier",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, McGill University, Montreal, QC, Canada."
}
},
{
"@type": "Person",
"name": "Wei Chen",
"url": "https://questionsmedicales.fr/author/Wei%20Chen",
"affiliation": {
"@type": "Organization",
"name": "Cancer Institute of Integrated Traditional Chinese and Western Medicine, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, PR China. viogro@163.com."
}
},
{
"@type": "Person",
"name": "Katherine L B Borden",
"url": "https://questionsmedicales.fr/author/Katherine%20L%20B%20Borden",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology and Cell Biology, Institute for Research in Immunology and Cancer, University of Montreal, Montreal, QC, Canada."
}
},
{
"@type": "Person",
"name": "Piotr Czapiewski",
"url": "https://questionsmedicales.fr/author/Piotr%20Czapiewski",
"affiliation": {
"@type": "Organization",
"name": "Institute of Pathology, Municipal Clinic Dessau, Dessau-Roßlau, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Reconstruction of Sparse-View X-ray Computed Tomography Based on Adaptive Total Variation Minimization.",
"datePublished": "2023-12-15",
"url": "https://questionsmedicales.fr/article/38138414",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/mi14122245"
}
},
{
"@type": "ScholarlyArticle",
"name": "Metallic artifacts-free spectral computed tomography angiography based on renal clearable bismuth chelate.",
"datePublished": "2023-12-14",
"url": "https://questionsmedicales.fr/article/38128318",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.biomaterials.2023.122422"
}
},
{
"@type": "ScholarlyArticle",
"name": "Computed tomographic diaphragmatic thickness: a promising method for the evaluation of diaphragmatic muscle in cardiopulmonary diseased cats.",
"datePublished": "2023-12-14",
"url": "https://questionsmedicales.fr/article/38164391",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fvets.2023.1247531"
}
},
{
"@type": "ScholarlyArticle",
"name": "Experimental and Computational Investigation of Microbubble Formation in a Single Capillary Embedded T-junction Microfluidic Device.",
"datePublished": "2023-12-12",
"url": "https://questionsmedicales.fr/article/38087401",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.langmuir.3c02982"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cardiac computed tomography angiography with and without bolus tracking methods in infants with congenital heart disease.",
"datePublished": "2023-12-12",
"url": "https://questionsmedicales.fr/article/38088430",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1093/rpd/ncad295"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines ribosomiques",
"item": "https://questionsmedicales.fr/mesh/D012269"
},
{
"@type": "ListItem",
"position": 5,
"name": "Facteurs initiation chaîne peptidique",
"item": "https://questionsmedicales.fr/mesh/D010448"
},
{
"@type": "ListItem",
"position": 6,
"name": "Facteurs d'initiation eucaryotes",
"item": "https://questionsmedicales.fr/mesh/D039642"
},
{
"@type": "ListItem",
"position": 7,
"name": "Facteur-4F d'initiation eucaryote",
"item": "https://questionsmedicales.fr/mesh/D039562"
},
{
"@type": "ListItem",
"position": 8,
"name": "Facteur-4G d'initiation eucaryote",
"item": "https://questionsmedicales.fr/mesh/D039603"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Facteur-4G d'initiation eucaryote - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Facteur-4G d'initiation eucaryote",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Facteur-4G d'initiation eucaryote",
"description": "Comment diagnostiquer une anomalie d'eIF-4G ?\nQuels tests sont utilisés pour évaluer eIF-4G ?\nLes biopsies peuvent-elles aider au diagnostic ?\nQuels marqueurs biologiques sont associés à eIF-4G ?\nL'imagerie est-elle utile pour diagnostiquer des troubles liés à eIF-4G ?",
"url": "https://questionsmedicales.fr/mesh/D039603?mesh_terms=Cloud+Computing&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Facteur-4G d'initiation eucaryote",
"description": "Quels symptômes sont liés à une dysfonction d'eIF-4G ?\nY a-t-il des symptômes neurologiques associés ?\nLes symptômes varient-ils selon l'âge ?\nDes symptômes immunitaires peuvent-ils apparaître ?\nLes symptômes sont-ils réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D039603?mesh_terms=Cloud+Computing&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Facteur-4G d'initiation eucaryote",
"description": "Peut-on prévenir les troubles liés à eIF-4G ?\nY a-t-il des mesures préventives recommandées ?\nLe suivi médical est-il important ?\nLes vaccinations peuvent-elles aider ?\nL'éducation génétique est-elle utile ?",
"url": "https://questionsmedicales.fr/mesh/D039603?mesh_terms=Cloud+Computing&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Facteur-4G d'initiation eucaryote",
"description": "Quels traitements sont disponibles pour les troubles d'eIF-4G ?\nLa nutrition joue-t-elle un rôle dans le traitement ?\nDes thérapies expérimentales existent-elles ?\nLes traitements sont-ils personnalisés ?\nLes traitements sont-ils efficaces à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D039603?mesh_terms=Cloud+Computing&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Facteur-4G d'initiation eucaryote",
"description": "Quelles complications peuvent survenir avec eIF-4G ?\nLes complications sont-elles graves ?\nY a-t-il des complications à long terme ?\nLes complications peuvent-elles être évitées ?\nComment gérer les complications liées à eIF-4G ?",
"url": "https://questionsmedicales.fr/mesh/D039603?mesh_terms=Cloud+Computing&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Facteur-4G d'initiation eucaryote",
"description": "Quels sont les facteurs de risque pour eIF-4G ?\nL'environnement influence-t-il eIF-4G ?\nL'alimentation peut-elle être un facteur de risque ?\nLes infections jouent-elles un rôle ?\nLe stress a-t-il un impact sur eIF-4G ?",
"url": "https://questionsmedicales.fr/mesh/D039603?mesh_terms=Cloud+Computing&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie d'eIF-4G ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses protéomiques peuvent identifier des anomalies."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer eIF-4G ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'électrophorèse et la PCR pour détecter des mutations."
}
},
{
"@type": "Question",
"name": "Les biopsies peuvent-elles aider au diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les biopsies tissulaires peuvent révéler des niveaux anormaux d'eIF-4G."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont associés à eIF-4G ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux de protéines spécifiques et des ARNm peuvent servir de marqueurs."
}
},
{
"@type": "Question",
"name": "L'imagerie est-elle utile pour diagnostiquer des troubles liés à eIF-4G ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie peut aider à évaluer des complications, mais pas directement eIF-4G."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une dysfonction d'eIF-4G ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des troubles de croissance et des anomalies métaboliques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent survenir en raison d'une mauvaise traduction."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent se manifester différemment selon l'âge du patient."
}
},
{
"@type": "Question",
"name": "Des symptômes immunitaires peuvent-ils apparaître ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une dysfonction d'eIF-4G peut affecter le système immunitaire."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils réversibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend de la cause sous-jacente et de la rapidité du traitement."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés à eIF-4G ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un dépistage génétique peut aider."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives recommandées ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des conseils sur la nutrition et le mode de vie peuvent être bénéfiques."
}
},
{
"@type": "Question",
"name": "Le suivi médical est-il important ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier peut aider à détecter des problèmes précocement."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations ne préviennent pas directement les troubles d'eIF-4G."
}
},
{
"@type": "Question",
"name": "L'éducation génétique est-elle utile ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur les risques génétiques peut aider à la prise de décision."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les troubles d'eIF-4G ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent inclure des thérapies géniques et des médicaments ciblés."
}
},
{
"@type": "Question",
"name": "La nutrition joue-t-elle un rôle dans le traitement ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une nutrition adéquate peut soutenir la fonction cellulaire et la traduction."
}
},
{
"@type": "Question",
"name": "Des thérapies expérimentales existent-elles ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des essais cliniques explorent de nouvelles approches thérapeutiques."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces à long terme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité dépend de la nature de la dysfonction et de la réponse au traitement."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec eIF-4G ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles métaboliques et des problèmes de croissance."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles graves ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être graves et nécessiter une intervention médicale."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications chroniques peuvent affecter la qualité de vie."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par un traitement précoce."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à eIF-4G ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi médical régulier et des traitements adaptés."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour eIF-4G ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des mutations génétiques et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "L'environnement influence-t-il eIF-4G ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains facteurs environnementaux peuvent affecter l'expression d'eIF-4G."
}
},
{
"@type": "Question",
"name": "L'alimentation peut-elle être un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation déséquilibrée peut influencer la fonction d'eIF-4G."
}
},
{
"@type": "Question",
"name": "Les infections jouent-elles un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent perturber la fonction d'eIF-4G et provoquer des troubles."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur eIF-4G ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut affecter la régulation de l'expression d'eIF-4G."
}
}
]
}
]
}
Sparse-view reconstruction has garnered significant interest in X-ray computed tomography (CT) imaging owing to its ability to lower radiation doses and enhance detection efficiency. Among current met...
Computed tomography angiography (CTA) is one of the most important diagnosis techniques for various vascular diseases in clinic. However, metallic artifacts caused by metal implants and calcified plaq...
Diaphragmatic dysfunction (DD) is defined as a weakening of the diaphragmatic muscle and can be an undetected cause of dyspnea. The objectives of this study were to explore the appropriate diaphragmat...
In recent years, there has been a notable increase in the interest toward microfluidic devices for microbubble synthesis. The upsurge can be primarily attributed to the exceptional control these devic...
The study investigated radiation dose, vascular computed tomography (CT) enhancement and image quality of cardiac computed tomography angiography (CCTA) with and without bolus tracking (BT) methods in...
The 1:1 complex formed from trifluoroacetic acid (TFA) and trimethylamine (TMA) has been observed in the gas phase by rotational spectroscopy and further investigated by DFT and MP2 methods. Spectra o...
Computed tomography urography (CTU) comprehensively evaluates the urinary tract. However, the procedure is associated with a high radiation dose due to multiple scan series and therefore requires opti...
The study was prospectively conducted on patients referred for CTU. The patients were grouped into A and B and were scanned with the standard protocol, a protocol used for the routine CTU at the CT ce...
The dose was significantly lower in the optimised protocol with a 10 % reduction in both volume computed tomography dose index and (CTDIvol) and dose length product (DLP) for the phantom images, and a...
The findings revealed a significant dose reduction in the optimised protocol. Further, image quality in standard and optimised protocols did not differ significantly based on quantitative and qualitat...
kV optimisation in contrast-enhanced procedures provides dose reduction and should be encouraged in the medical imaging departments....
Microvascular invasion (MVI) is a common complication of hepatocellular carcinoma (HCC) surgery, which is an important predictor of reduced surgical prognosis. This study aimed to develop a fully auto...
A total of 140 patients with HCC from two centers were retrospectively included (training set, n = 98; testing set, n = 42). All CT phases were aligned to the portal venous phase, and were then used t...
Overall, 86 and 54 patients with MVI- (age, 55.92 ± 9.62 years; 68 men) and MVI+ (age, 53.59 ± 11.47 years; 43 men) were included. Average dice coefficients of liver tumor segmentation were 0.89 and 0...
The classification model based on multimodal intra- and peri-tumoral radiomics features can well predict HCC patients with MVI....
Breast ultrasound computed tomography (USCT) has been gradually promoted to clinical application after years of rapid development. Compared with the traditional handheld ultrasound scanning method, th...
Cerebral arterial gas embolism (CAGE) occurs when air or medical gas enters the systemic circulation during invasive procedures and lodges in the cerebral vasculature. Non-contrast computer tomography...
This is a retrospective single-center cohort study. We included patients who were diagnosed with iatrogenic CAGE and underwent CTP within 24 h after onset of symptoms between January 2016 and October ...
Among 27 patient admitted with iatrogenic CAGE, 15 patients underwent CTP within the designated timeframe and were included for imaging analysis. CTP showed perfusion deficits in all patients except o...
CTP may show specific perfusion defects in patients with a clinical diagnosis of CAGE. This suggests that CTP may be supportive in diagnosing CAGE in cases where no intracerebral gas is seen on non-co...